Bispecific Antibody Development Services

Creative Biolabs offers comprehensive bispecific antibody production services to support the development of novel therapeutics. Our experienced team of scientists can assist with the design, construction, expression, purification, and characterization of bispecific antibodies using state-of-the-art equipment and techniques.

Services

Bispecific antibodies are a powerful class of molecules that can simultaneously bind two different targets, allowing for enhanced targeting of specific cells or molecules. Normally, the main production process involves the creation of two monoclonal antibodies, which are then fused to form a single bispecific antibody. In Creative Biolabs, these antibodies can be produced using various formats, including bispecific T cell engagers, bispecific antibody fragments, Fc silent bispecific antibodies, dual targeting bispecific antibodies, and bispecific IgG antibodies.

• Bispecific Antibody Target Validation: Our service involves the validation of bispecific antibody targets using in vitro and in vivo assays. Our assays can identify and validate novel targets for bispecific antibody therapy to address unmet medical needs in different disease models.
• Bispecific Antibody Development: Creative Biolabs provides services for the preclinical development of bispecific antibodies, such as lead optimization, preclinical testing, and therapeutic potential assessment.
• Bispecific Antibody Engineering: Our service involves the design and development of bispecific antibodies using cutting-edge antibody engineering techniques. We can optimize antibody specificity, affinity, and stability to enhance their efficacy in targeting specific cells or molecules.
• Bispecific Antibody Production: We offer services for the large-scale production of bispecific antibodies using cell culture techniques. In our labs, our scientists can offer clone selection, cell line development, and antibody purification to generate high-quality bispecific antibodies for preclinical studies.
• Bispecific Antibody Characterization: Our service involves the comprehensive analysis of bispecific antibodies to assess their binding specificity, affinity, stability, and functional activity. Moreover, we can also evaluate the pharmacokinetics, pharmacodynamics, and safety profile of bispecific antibodies for our clients.
• Bispecific Antibody Conjugation: It involves the covalent attachment of a bispecific antibody to a payload or a targeting ligand, such as a drug molecule or a fluorescent dye. This process is essential for creating targeted therapeutics that can deliver drugs specifically to cancer cells or other diseased tissues while minimizing off-target effects.

Fig.1 Bispecific Antibody Types.^1,3

Platform

In Creative Biolabs, there are a variety of bispecific antibody production services available that cater to different research and therapeutic needs. Our services offer customizable solutions for the design, expression, purification, and characterization of bispecific antibodies. Some characteristics of these services include high purity, low endotoxin levels, and high yields. The advantages of using these services include reduced production time, cost-effectiveness, and expert technical support throughout the production process.

CrossMab Platform: This platform involves the use of two different antibody fragments, one targeting the primary antigen and the other targeting a secondary antigen. The fragments are fused using a flexible linker, creating a bispecific antibody that can bind to both antigens simultaneously. The CrossMab platform offers enhanced flexibility and customization, as well as improved pharmacokinetics and efficacy.

Dual Targeting Ig Platform: This platform utilizes two variable domains, one from each parent antibody, to create a bispecific antibody with dual specificity. Our platform allows for precise and predictable engineering of bispecific antibodies, with enhanced stability and potency compared to traditional approaches.

Trifunctional antibody Platform: This platform involves the use of a tri-specific antibody, with binding sites for three different antigens. Hybrid antibodies are engineered to simultaneously target multiple antigens on the same cell or different cells, providing enhanced therapeutic benefits compared to traditional monoclonal antibodies. The platform offers improved target specificity and potency, making it a promising option for cancer therapy.

Fig.2 Bispecific Antibody Production Service Process. (Creative Biolabs Original)

Advantages

• Enhanced efficacy: Bispecific antibodies can simultaneously target two different antigens, leading to enhanced efficacy compared to traditional monoclonal antibodies that only target one antigen.
• Versatility: Various production techniques allow for the creation of bispecific antibodies with different specificities and formats, providing versatility for different therapeutic applications.
• Reduced off-target effects: Bispecific antibodies can be designed to selectively target tumor cells while sparing healthy cells, reducing off-target effects and potentially improving safety profiles.
• Improved pharmacokinetics: By utilizing different production techniques, bispecific antibodies can be engineered with optimized pharmacokinetic properties, allowing for prolonged circulation and improved half-life in the body.
• Potential for personalized medicine: The flexibility of production techniques enables the customization of bispecific antibodies for specific patient populations or disease subtypes, allowing for personalized treatment approaches.

Case Study

As an example of our bispecific antibody production capabilities, we recently completed a bispecific antibody project in the biopharmaceutical industry. This project required a bispecific antibody targeting both HER2 and CD3 receptors for use in cancer therapy. Our team successfully designed and produced the bispecific antibody using a mammalian expression system. The antibody demonstrated high binding affinity to both targets and potent cytotoxic activity against HER2-expressing cancer cells in vitro. This case highlights our expertise in bispecific antibody production and our ability to deliver high-quality products for various applications.

Fig.3 Highly Specific Antitumor Action Mediated By a HER2-CD3-Fc bsAb.^2,3

Whether you are looking to explore new targets, improve the therapeutic efficacy of existing antibodies, or develop innovative bi-specific antibody-based therapeutics, Creative Biolabs can provide the expertise and resources needed to accelerate your research and development efforts. If you require bispecific antibody production services, look no further! Contact us to discuss your project requirements and learn more about how we can help you achieve your research or therapeutic goals.

References

1. Hoseini, S. S., and N. K. Cheung. "Acute myeloid leukemia targets for bispecific antibodies." Blood cancer journal 7.2 (2017): e522-e522.
2. Hu, Liang, et al. "HER2-CD3-Fc Bispecific Antibody-Encoding mRNA Delivered by Lipid Nanoparticles Suppresses HER2-Positive Tumor Growth." Vaccines 12.7 (2024): 808.
3. under Open Access License CC BY 4.0, without modification.

For research use only. Not intended for any clinical use.